Back to results
US 2026/0097048 A1Published application
Treatment of prostate cancer with a combination of abiraterone acetate and niraparib
AssigneeJanssen Pharmaceutica NV
InventorsThomas Ronald A. QUINTEN, Urbain Alfons C. DELAET, Philip Erna H. HEYNS, Tatiana MARCOZZI, Johny BERTELS, Katrien LUYTEN, Kaustubh Ramesh TAMBWEKAR, Angela LOPEZ-GITLITZ, Paul J. A. HARTMAN KOK
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a combination of abiraterone acetate and niraparib, free-dose and fixed-dose combinations of abiraterone acetate and niraparib, and methods of treatment of prostate cancer with said combinations.
Claims19
A granule composition comprising abiraterone acetate, niraparib tosylate monohydrate, and a pharmaceutically acceptable carrier;
- wherein said pharmaceutically acceptable carrier comprises sodium lauryl sulfate (SLS), wherein SLS is present in the granule composition in a by weight ratio versus abiraterone acetate of about 0.005:1 to 0.02:1 (SLS:
- abiraterone acetate).
Dependencies are inferred from the claim text.